Board Member
Amylyx Pharmaceuticals, Inc. (AMLX)Equibles does not estimate personal net worth.
Get an email with a short summary when Amylyx Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get AMLX alertsJustin Klee is recorded as Board Member at Amylyx Pharmaceuticals, Inc. (AMLX) since January 1, 2014 and CEO at Amylyx Pharmaceuticals, Inc. (AMLX). The newest filing on record that lists Justin Klee as CEO and Board Member at Amylyx Pharmaceuticals, Inc. (AMLX) is dated April 23, 2026. The proxy statement of Amylyx Pharmaceuticals, Inc. reports total compensation of $2,719,807 for Justin Klee in fiscal 2025, including a base salary of $686,200. Disclosed compensation is on record for 6 fiscal years. Justin Klee has spoken on 17 earnings calls and 3 other investor events across 1 company, most recently for Amylyx Pharmaceuticals, Inc. on November 9, 2026. Amylyx Pharmaceuticals, Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Amylyx Pharmaceuticals, Inc. includes Joshua Cohen (CEO and Board Member), James Frates (CFO), Gina M. Mazzariello (General Counsel) and 2 others.
“And I appreciate the nod to our prior launch. We're very proud of the work we did there. But, of course, there are always lessons learned, so we hope to do even better this time.”
“It has been a momentous period for AMLIX. In the third quarter, we reported positive top-line results from the Phase III lucidity trial of the Bexatide, an investigational first-in-class GLP-1 receptor antagonist in participants with postbariatric hypoglycemia, or PVH, following RUIN-Y gastric bypass surgery.”
“Well, I think that I'd start with the prior work that had been done in post-bariatric hypoglycemia. So post-bariatric hypoglycemia, PBH, doesn't occur in most people.”
“This is an exciting time for AMLEX and the post-bariatric hypoglycemia community as we approach the pivotal Phase III Lucidity Topline data readout.”
“Well, first, thanks so much for having us. We're thrilled to be here. So, So Justin, co-CEO, co-founder at Amlex, we have a number of exciting programs under development.”
2014-01-01–present
Last confirmed April 23, 2026
Start not stated–present
Last confirmed April 23, 2026
Drug Manufacturers - Specialty & Generic · Healthcare
CEO, Board Member
2014-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Amylyx Pharmaceuticals, Inc. (AMLX) | Co-Chief Executive Officer and Director | $686,200 | $2,719,807 |
| 2024 | Amylyx Pharmaceuticals, Inc. (AMLX) | Co-Chief Executive Officer and Director | $686,200 | $6,496,255 |
| 2023 | Amylyx Pharmaceuticals, Inc. (AMLX) | Co-Chief Executive Officer and Director | $621,000 | $7,418,169 |
| 2022 | Amylyx Pharmaceuticals, Inc. (AMLX) | Co-Chief Executive Officer and Director | $539,275 | $7,178,416 |
| 2021 | Amylyx Pharmaceuticals, Inc. (AMLX) | Co-Chief Executive Officer and Director | $417,833 | $1,424,533 |
| 2020 | Amylyx Pharmaceuticals, Inc. (AMLX) | Co-Chief Executive Officer and Director | $370,000 | $670,500 |
